Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
ASAS-normen bieden kwalitatief hoogwaardig zorgkader
nov 2019 | Spondyloartritis